"Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study" was originally created and published by ...

AN Alzheimer’s drug which has been rejected for NHS use can slow disease progression by eight years, researchers have claimed ...

The phase 2a trial is currently enrolling patients; updated clinical data are expected by the end of 2025. The Food and Drug Administration (FDA) has granted Fast Track designation to troculeucel, an ...

Final data from the ELAD trial showed that treatment with liraglutide (Saxenda, Victoza) in people with mild to moderate ...

Eisai Presents New Data On The Continued And Expanding Benefit Of LEQEMBI(R) (Lecanemab-Irmb) Maintenance Treatment In Early Alzheimer's Disease At CTAD 2025. Eisai Presents New Data on the Continued ...

Seeking Alignment with European Medicines Agency (EMA) at February 2026 Meeting -- Actively Evaluating Strategy Across DLB and Alzheimer’s ...

Zunveyl is supplied as 5mg, 10mg, and 15mg delayed-release tablets, which can be taken with or without food. Zunveyl ® (benzgalantamine) is now available for the treatment of mild to moderate dementia ...

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January ...

Moderate amount of caring for grandchildren significantly reduces dementia risk in older adults, according to a major new study that followed more than 10,000 Chinese adults for five years.

July 12, 2010 (Honolulu, Hawaii) — A new analysis from the Framingham Study suggests moderate to heavy physical activity is associated with a reduced risk for dementia during more than 20 years of ...